Beyond the Scan: Are We Ready for One-Stop Heart Health Assessments?
"Combining Coronary Anatomy and Hemodynamics for Comprehensive Cardiac Care"
For individuals dealing with coronary artery disease, determining the presence of ischemia is crucial because it significantly influences prognosis and helps identify those most likely to benefit from revascularization. It's important to recognize that the severity of a coronary stenosis alone doesn't dictate downstream myocardial perfusion. Recent trials using invasive fractional flow reserve (FFR) have demonstrated that basing revascularization decisions on whether a coronary stenosis is hemodynamically significant, rather than just its anatomical severity, improves patient outcomes.
These studies also indicate that non-hemodynamically significant coronary stenoses can be safely managed with medical therapy alone. Conversely, relying solely on medical management for hemodynamically significant stenoses may lead to poorer outcomes. While FFR is a valuable tool for assessing the hemodynamic significance of coronary stenosis, it remains an invasive procedure. Thus, there's a continuing need for a noninvasive method to determine both the presence of a coronary stenosis and its hemodynamic significance.
Ideally, such a strategy would provide comprehensive anatomic and functional data about coronary artery disease accurately, cost-effectively, and conveniently, ultimately enhancing patient outcomes and guiding treatment plans.
Coronary Disease and Assessment
Coronary artery disease (CAD) is described as a leading cause of death globally and one of the most commonly diagnosed manifestations of heart disease in a 2025 review. The CDC snippet reports 13.0 million physician-office visits in 2019 with coronary atherosclerosis and other chronic ischemic heart disease as the primary diagnosis, and says CAD, ischemic heart disease, or a history of myocardial infarction appeared in 6.9% of visit records. In stable chest pain, adding fractional flow reserve (FFR) to angiographic assessment can identify physiologically significant lesions that their appearance alone poorly predicts. A nationwide study describes timely diagnosis and risk stratification as relying on multiple noninvasive imaging modalities, and examines trends across them.
Imaging in CAD Evaluation
Noninvasive imaging has a fundamental role in evaluating and managing patients with known or suspected coronary artery disease (CAD), according to the American Society of Echocardiography. Imaging endpoints have also served as surrogate markers in observational studies and randomized clinical trials. A study of the natural history of coronary atherosclerosis describes assessment by coronary angiography and examines progression of nonobstructive CAD by anatomic location and selected risk factors, including diabetes, hypertension, hyperlipidaemia, and current smoking.
The Promise of CCTA: Visualizing Anatomy and Function
Coronary computed tomography angiography (CCTA) emerges as a precise, noninvasive imaging technique, delivering a comprehensive anatomical evaluation of coronary arteries comparable to invasive coronary angiography. Its high negative predictive value makes CCTA useful for identifying patients with nonobstructive disease who could benefit from medical therapy. However, CCTA alone doesn't provide information on the functional significance of a visualized lesion. Assessing the severity of stenosis can also be challenging in the presence of coronary calcification, stents, and bypass grafts.
- CT-FFR (Computed Tomography Fractional Flow Reserve): This technique applies computational fluid dynamics to derive FFR values from standard CCTA images, eliminating the need for pharmacologic stress agents, additional image acquisitions, or more contrast.
- CTP (Computed Tomography Perfusion): As an alternative, vasodilator CTP can be performed in patients with potentially significant coronary artery stenosis detected during CCTA. This helps determine which stenoses are hemodynamically significant and potential targets for revascularization.
Evolving Noninvasive Testing
A 2025 review describes CAD as narrowing or blockage of coronary arteries that reduces delivery of oxygen-rich blood to the heart muscle. It notes that symptoms vary widely and can be confused with other medical conditions. A separate review argues that continued investigation of noninvasive diagnostic methods beyond coronary CT angiography (CCTA), alongside technological innovations, is needed to improve diagnostic precision and patient care. Noninvasive modalities identified in another review include echocardiography, CCTA, cardiac magnetic resonance, and SPECT myocardial perfusion imaging.
Limits of Noninvasive Testing
The FDA review cautions that results may not generalize beyond the population studied: people with coronary artery disease symptoms who had a CT scan and were scheduled for diagnostic angiography. A systematic review illustrates a potential classification error: a lesion with FFR-CT of 0.81 but invasive FFR of 0.79 could be considered non-hemodynamically significant if imaging alone were relied on. A 2020 study notes that more than 4 million cardiac noninvasive diagnostic tests are performed annually for stable coronary artery disease in the United States, while whether they improve downstream outcomes remains unclear. A 2025 review also describes invasive coronary angiography as the gold standard for detecting CAD, while noting its limitations.
FFR-CT Diagnostic Performance
In the NXT trial, the area under the receiver-operating-characteristic curve for FFR-CT was 0.90 (95% confidence interval 0.87–0.94), compared with 0.81 (0.76–0.87) for coronary CT angiography; the reported difference was statistically significant (p = 0.0008). A systematic review and meta-analysis reported patient-based pooled sensitivity of 0.89 and specificity of 0.76 for FFR-CT detection of ischemic lesions, with a diagnostic odds ratio of 26.21. These findings provide different kinds of evidence: the NXT result compares discrimination in a trial, while the meta-analysis summarizes pooled diagnostic estimates. The supplied snippets do not establish that these estimates apply uniformly across clinical settings.
The Horizon of Cardiac Diagnostics
The integration of CCTA with CTP holds great promise for enhancing cardiac diagnostics, potentially reducing the need for invasive procedures and improving patient outcomes. As research continues and technology advances, the ability to comprehensively assess coronary anatomy and function noninvasively moves closer to becoming a clinical reality, offering a more streamlined, patient-friendly approach to managing heart disease.
Noninvasive Assessment and Early Detection
A 2025 Cureus review describes coronary artery disease as a significant public health concern because of its morbidity and mortality, and says early detection and timely evaluation are important for improving patient outcomes. It notes that both invasive and noninvasive methods are available for assessing CAD risk. The review says noninvasive approaches minimize complications associated with invasive procedures. These points support considering noninvasive assessment as part of evaluation, without establishing that any particular one-stop assessment improves outcomes.